Novartis beats Kesimpta sales expectations in Q4
Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
by marketwire, translated by daniel pedersen
Swiss pharmaceutical giant Norvatis has exceeded sales expectations for multiple sclerosis treatment Kesimpta in the fourth quarter of 2022, revealed an annual report on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Denmark rejects Janssen and Genmab drug twice in January
For subscribers
Three Genmab cancer drugs close in on big milestones in 2023
For subscribers
.jpg&w=384&q=75)
